SQLE is a promising prognostic and immunological biomarker and correlated with immune Infiltration in Sarcoma

Mengwei Shao,Mingbo Wang,Xiliang Wang,Xiaodong Feng,Lifeng Zhang,Huicheng Lv

DOI: https://doi.org/10.1097/md.0000000000037030

IF: 1.6

2024-02-10

Medicine

Abstract:Sarcoma is a rare and heterogeneous group of malignant tumors that arise from mesenchymal cells, including bone, cartilage, fat, and muscle. Sarcoma accounts for less than 1% of all adult cancers, and the overall incidence of sarcoma is about 5–6 cases per 100,000 people per year. [ 1 ] Despite advances in diagnosis and treatment, the prognosis for patients with sarcoma remains poor, with a 5-year survival rate of less than 50%. [ 2 ] The etiology of sarcomas is largely unknown, although certain environmental and genetic factors have been implicated in their development. At the molecular level, sarcomas are characterized by complex genetic and epigenetic alterations, which contribute to their pathogenesis and progression. [ 3 ] The pathological and physiological mechanisms underlying sarcomagenesis are also complex and poorly understood. Currently, the diagnosis of sarcoma relies on a combination of imaging studies, histopathology, and molecular testing. Treatment options for sarcoma include surgery, radiation therapy, chemotherapy, and targeted therapy. [ 4 ] However, the efficacy of these treatments is limited, and many patients experience relapse or disease progression. Therefore, there is a pressing need for a better understanding of the molecular and cellular mechanisms underlying sarcoma pathogenesis and for the development of novel therapeutic strategies.

medicine, general & internal